JP2005516986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516986A5 JP2005516986A5 JP2003565415A JP2003565415A JP2005516986A5 JP 2005516986 A5 JP2005516986 A5 JP 2005516986A5 JP 2003565415 A JP2003565415 A JP 2003565415A JP 2003565415 A JP2003565415 A JP 2003565415A JP 2005516986 A5 JP2005516986 A5 JP 2005516986A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- amino
- oxime
- carbonyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 dibenzofuranyl Chemical group 0.000 claims 49
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 49
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 47
- 150000002923 oximes Chemical class 0.000 claims 47
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 12
- 239000003085 diluting agent Substances 0.000 claims 12
- 239000003937 drug carrier Substances 0.000 claims 11
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 claims 2
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 2
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QJLORVSDABTRCS-UHFFFAOYSA-N phenyl n-(4-undecoxyphenyl)carbamate Chemical compound C1=CC(OCCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 QJLORVSDABTRCS-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- OHKUODJKULFCPB-UHFFFAOYSA-N (2,4-difluorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(F)C=C1F OHKUODJKULFCPB-UHFFFAOYSA-N 0.000 claims 1
- PWZMFAZZDZNTOQ-UHFFFAOYSA-N (2-fluorophenyl) n-(4-decoxyphenyl)carbamate Chemical compound C1=CC(OCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1F PWZMFAZZDZNTOQ-UHFFFAOYSA-N 0.000 claims 1
- PHBVHSXINCCZDW-UHFFFAOYSA-N (2-fluorophenyl) n-(4-octoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1F PHBVHSXINCCZDW-UHFFFAOYSA-N 0.000 claims 1
- XSSVFUMMMRTXER-UHFFFAOYSA-N (2-fluorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=CC=C1F XSSVFUMMMRTXER-UHFFFAOYSA-N 0.000 claims 1
- GDLJXVIFSNBWKP-UHFFFAOYSA-N (2-fluorophenyl) n-[1-(4-butoxyphenyl)propyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1C(CC)NC(=O)OC1=CC=CC=C1F GDLJXVIFSNBWKP-UHFFFAOYSA-N 0.000 claims 1
- RFAALCRYXIMHGO-UHFFFAOYSA-N (3-chlorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=CC(Cl)=C1 RFAALCRYXIMHGO-UHFFFAOYSA-N 0.000 claims 1
- BVPXJSVMJYBIRX-UHFFFAOYSA-N (4-fluorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical group C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(F)C=C1 BVPXJSVMJYBIRX-UHFFFAOYSA-N 0.000 claims 1
- IEKBPHHXDXKATO-UHFFFAOYSA-N (4-fluorophenyl) n-[1-(4-butoxyphenyl)propyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1C(CC)NC(=O)OC1=CC=C(F)C=C1 IEKBPHHXDXKATO-UHFFFAOYSA-N 0.000 claims 1
- LCRIEQJXNHPILH-UHFFFAOYSA-N (4-methoxyphenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(OC)C=C1 LCRIEQJXNHPILH-UHFFFAOYSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 claims 1
- CYIFJRXFYSUBFW-UHFFFAOYSA-N 2,4,5-trifluorobenzaldehyde Chemical compound FC1=CC(F)=C(C=O)C=C1F CYIFJRXFYSUBFW-UHFFFAOYSA-N 0.000 claims 1
- SOWRUJSGHKNOKN-UHFFFAOYSA-N 2,6-difluorobenzaldehyde Chemical compound FC1=CC=CC(F)=C1C=O SOWRUJSGHKNOKN-UHFFFAOYSA-N 0.000 claims 1
- XDMZVNQKVMTCSP-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzaldehyde Chemical compound FC1=C(C=O)C=CC=C1C(F)(F)F XDMZVNQKVMTCSP-UHFFFAOYSA-N 0.000 claims 1
- IDLNLGMUINCSGS-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzaldehyde Chemical compound FC1=CC=C(C(F)(F)F)C=C1C=O IDLNLGMUINCSGS-UHFFFAOYSA-N 0.000 claims 1
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 claims 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 claims 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000004634 feeding behavior Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- ZNJJGGVTHHJCRN-UHFFFAOYSA-N phenyl n-(4-decoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 ZNJJGGVTHHJCRN-UHFFFAOYSA-N 0.000 claims 1
- DFYYHKJFWVSJHM-UHFFFAOYSA-N phenyl n-(4-dodecoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 DFYYHKJFWVSJHM-UHFFFAOYSA-N 0.000 claims 1
- JPIYDITTWBUFSY-UHFFFAOYSA-N phenyl n-(4-heptoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 JPIYDITTWBUFSY-UHFFFAOYSA-N 0.000 claims 1
- IJCMIOMSKCNMQY-UHFFFAOYSA-N phenyl n-(4-octoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 IJCMIOMSKCNMQY-UHFFFAOYSA-N 0.000 claims 1
- ZUXSLOOOUXPMLR-UHFFFAOYSA-N phenyl n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=CC=C1 ZUXSLOOOUXPMLR-UHFFFAOYSA-N 0.000 claims 1
- RENASMKOGKEGAN-UHFFFAOYSA-N quinolin-6-yl n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(N=CC=C2)C2=C1 RENASMKOGKEGAN-UHFFFAOYSA-N 0.000 claims 1
- GNIJWICZUOBESL-UHFFFAOYSA-N quinolin-6-yl n-[1-(4-butoxyphenyl)propyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1C(CC)NC(=O)OC1=CC=C(N=CC=C2)C2=C1 GNIJWICZUOBESL-UHFFFAOYSA-N 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35530202P | 2002-02-08 | 2002-02-08 | |
| PCT/US2003/003222 WO2003065989A2 (en) | 2002-02-08 | 2003-02-04 | (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516986A JP2005516986A (ja) | 2005-06-09 |
| JP2005516986A5 true JP2005516986A5 (enExample) | 2006-02-02 |
Family
ID=27734499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565415A Withdrawn JP2005516986A (ja) | 2002-02-08 | 2003-02-04 | （オキシム）カルバモイル脂肪酸アミド加水分解酵素インヒビター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6949574B2 (enExample) |
| EP (1) | EP1472215A4 (enExample) |
| JP (1) | JP2005516986A (enExample) |
| AU (1) | AU2003210824A1 (enExample) |
| PL (1) | PL373970A1 (enExample) |
| WO (1) | WO2003065989A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158131A0 (en) | 2001-03-27 | 2004-03-28 | Univ California | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
| US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
| US7750030B2 (en) * | 2001-03-29 | 2010-07-06 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
| KR20050088992A (ko) | 2002-10-07 | 2005-09-07 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 아난드아미드 가수분해 차단을 통한 불안감의 조절 |
| FR2850377B1 (fr) | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2860514A1 (fr) * | 2003-10-03 | 2005-04-08 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| CA2542547A1 (en) * | 2003-10-16 | 2005-05-26 | Daniele Piomelli | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| RS56194B1 (sr) | 2004-12-30 | 2017-11-30 | Janssen Pharmaceutica Nv | Derivativi fenilamida 4-(benzil)-piperazin-1-karboksilne kiseline i slična jedinjenja kao modulatori hidrolaze amida masnih kiselina (faah) za lečenje anksioznosti, bola i ostalih stanja |
| EP2607362B1 (en) | 2005-02-17 | 2014-12-31 | Astellas Pharma Inc. | Piperidine and piperazine carboxylates as FAAH inhibitors |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| WO2007061862A2 (en) * | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| US20070155707A1 (en) * | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| JPWO2008023720A1 (ja) | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| CA2674359A1 (en) * | 2006-11-20 | 2008-05-29 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| CN101631768A (zh) * | 2007-03-15 | 2010-01-20 | 太阳医药高级研究有限公司 | 新型前药 |
| US20100311711A1 (en) * | 2007-10-11 | 2010-12-09 | The Regents Of The University Of California | Inhibitors of NAAA and Methods Thereof |
| EP2062578A1 (en) * | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
| TW201006791A (en) * | 2008-05-15 | 2010-02-16 | Sigma Tau Ind Farmaceuti | Oxime carbamoyl derivatives as modulators of fatty acid amide hydrolase |
| US8207226B1 (en) | 2008-06-03 | 2012-06-26 | Alcon Research, Ltd. | Use of FAAH antagonists for treating dry eye and ocular pain |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| KR20110091508A (ko) | 2008-11-06 | 2011-08-11 | 아스텔라스세이야쿠 가부시키가이샤 | 카르바메이트 화합물 또는 그의 염 |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| WO2012058115A2 (en) * | 2010-10-28 | 2012-05-03 | Benjamin Cravatt | Anti-cancer serine hydrolase inhibitory carbamates |
| CA2856522C (en) | 2011-11-22 | 2020-10-27 | The Regents Of The University Of California | Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa) |
| EP2931291B1 (en) | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| US9474271B2 (en) | 2013-01-18 | 2016-10-25 | Research Foundation Of The City University Of New York | Method for enhancing amidohydrolase activity of fatty acid amide hydrolase |
| WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| WO2014144836A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| CN105418460B (zh) * | 2014-08-11 | 2017-04-12 | 苏州鹏旭医药科技有限公司 | 匹莫范色林及其类似化合物中间体，其制备方法和制备匹莫范色林及其类似化合物的方法 |
| JP7200261B2 (ja) * | 2017-12-05 | 2023-01-06 | スージョウ ポンシュー ファーマテック カンパニー リミテッド | エラゴリクスを作製するプロセス |
| US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB841141A (en) * | 1955-08-29 | 1960-07-13 | Union Carbide Corp | Naphthyl esters of n-alkyl-substituted carbamic acids and insecticidal compositions containing the same |
| NL302370A (enExample) * | 1962-12-22 | |||
| DE1232947B (de) * | 1963-12-09 | 1967-01-26 | Fahlberg List Chemische Veb | Verfahren zur Herstellung von Ketoximcarbanilaten aus Ketoximen und Arylisocyanaten |
| AU619038B2 (en) * | 1988-08-24 | 1992-01-16 | Teijin Limited | Oxime derivatives and herbicides containing the same as an active ingredient |
| GB9719530D0 (en) * | 1997-09-12 | 1997-11-19 | Smithkline Beecham Plc | Novel compounds |
| IL158300A0 (en) * | 2001-04-27 | 2004-05-12 | Bristol Myers Squibb Co | Bisarylimidazol derivatives and pharmaceutical compositions containing the same |
-
2003
- 2003-02-04 PL PL03373970A patent/PL373970A1/xx unknown
- 2003-02-04 WO PCT/US2003/003222 patent/WO2003065989A2/en not_active Ceased
- 2003-02-04 US US10/357,807 patent/US6949574B2/en not_active Expired - Lifetime
- 2003-02-04 AU AU2003210824A patent/AU2003210824A1/en not_active Abandoned
- 2003-02-04 JP JP2003565415A patent/JP2005516986A/ja not_active Withdrawn
- 2003-02-04 EP EP03737600A patent/EP1472215A4/en not_active Withdrawn
-
2005
- 2005-01-19 US US11/039,516 patent/US20050131032A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516986A5 (enExample) | ||
| JP4896518B2 (ja) | ニコチンアミド系キナーゼ阻害薬 | |
| AU2006200717B8 (en) | Isoindole-imide compounds, compositions, and uses thereof | |
| CH616674A5 (enExample) | ||
| JP2005528325A5 (enExample) | ||
| JP2005516986A (ja) | （オキシム）カルバモイル脂肪酸アミド加水分解酵素インヒビター | |
| CN108698991B (zh) | 2-氧代吲哚化合物 | |
| JPH08504435A (ja) | タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン | |
| JP2006514626A5 (enExample) | ||
| RU2006109108A (ru) | Соединения, обладающие активностью антагонистов crth2 рецепторов | |
| JP2011148809A (ja) | 抗腫瘍作用を有するインドリル−３−グリオキシル酸誘導体 | |
| WO2000076984A8 (en) | Novel compounds, their use and preparation | |
| US20080032965A1 (en) | Method for enhancing cognitive function | |
| AU2019263176A1 (en) | Compounds for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | |
| JPH07509219A (ja) | Ｈ↓３受容体アンタゴニストとしての４−［４’−ピペリジニルまたは３’−ピロリジニル］置換イミダゾールおよび治療上のその使用方法 | |
| JP2002030084A5 (enExample) | ||
| CN1268122A (zh) | 用作nos抑制剂的支化烷氧基取代的2－氨基吡啶 | |
| JP2002544193A (ja) | Ｐｄｅ４阻害薬としてのヘテロ置換ピリジン誘導体 | |
| AU681601B2 (en) | O-aryl ethers of morphinans | |
| JPH0791289B2 (ja) | アミノ酸誘導体 | |
| JP2846895B2 (ja) | 抗痙攣用または神経保護用医薬 | |
| JP2008508251A5 (enExample) | ||
| JP2001515509A (ja) | 新規キノリン−およびナフタレンカルボキサミド、医薬組成物およびカルパインの阻害方法 | |
| JP2005517634A5 (enExample) | ||
| KR101160858B1 (ko) | 소양 치료약으로서 유용한 4-(2-푸로일)아미노피페리딘류 |